相关实验视频

Updated: Jul 9, 2026

Acute Myocardial Infarction in Rats

Acute Myocardial Infarction in Rats

Published on: February 16, 2011

抑制NKCC1作为对抗凝血病的突破,并在LPS诱导的DIC大鼠模型中提高存活率

Hao-Yuan Hung¹, Chih-Chin Shih², Mei-Hui Liao³

¹Graduate Institute of Pharmacology, College of Pharmacy, National Defense Medical University, Taipei, Taiwan, Republic of China; Department of Pharmacy Practice, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan, Republic of China.

European journal of pharmacology

|November 8, 2025

概括

富罗塞米德在治疗败血症引起的凝血病和器官功能障碍方面表现有前途. 这种利尿剂通过抑制NKCC1来降低炎症和氧化应激,在毒症并发症的小鼠模型中提高了生存率.

科学领域:

生物医学研究的研究.
药理学药理学是指药理学的学科.
关键护理医学关键护理医学

背景情况:

败血症会引发炎症,氧化应激和凝血病,往往导致DIC和MODS.
罗斯米德是一种利尿剂,抑制NKCC1并具有抗炎和抗氧化特性.

研究的目的:

为了研究furosemide在脂聚糖 (LPS) 诱导的散布式血管内凝血 (DIC) 类似的小鼠模型中的治疗潜力.
为了评估furosemide对凝血病,器官功能障碍和败血症生存的影响.

主要方法:

雄性Wistar大鼠被分为对照组,治疗罗斯米德的对照组,LPS诱导的和治疗罗斯米德的LPS组.
使用基于ISTH标准的评分系统来评估凝血病.
分析了生物化学标记物,血液流动,炎症性细胞因子,超氧化物,氧化和NKCC1的表达.

主要成果:

低血压导致严重的凝血病,多器官功能障碍和高死亡率.
罗塞米德治疗显著缓解了凝血病,有限的器官功能障碍,并改善了生存率.
罗塞米德的作用与减少炎症,氧化应激和潜在的NKCC1抑制有关.

结论:

富罗塞米德在治疗LPS诱导的DIC和败血症相关并发症方面显示出显著的治疗潜力.
富洛塞米德的抗炎和抗氧化特性,可能通过NKCC1抑制,是其保护作用的基础.
富罗塞米德可能是治疗败血症的可行的重用药物.

关键词:

凝血病是一种凝血病.散布的血管内凝血.二化物是一种二化物.纳+) -K+) -2Cl−) 是一个共载体.败血症这是一种败血症.

更多相关视频

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

相关概念视频

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).